MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
16 déc. 2020 16h30 HE
|
MacroGenics, Inc.
MARGENZA (margetuximab-cmkb) is the first HER2-targeted therapy to have improved progression-free survival (PFS) versus Herceptin® (trastuzumab), both combined with chemotherapy, in a head-to-head...
MacroGenics Provides Update on Corporate Progress and Third Quarter 2020 Financial Results
04 nov. 2020 16h01 HE
|
MacroGenics, Inc.
ROCKVILLE, Md., Nov. 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Provides Update on Corporate Progress and Second Quarter 2020 Financial Results
30 juil. 2020 16h01 HE
|
MacroGenics, Inc.
ROCKVILLE, Md., July 30, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Date of Second Quarter 2020 Financial Results Conference Call
23 juil. 2020 07h30 HE
|
MacroGenics, Inc.
Rockville, MD, July 23, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Lancet Oncology Publication of Margetuximab Data in Gastric Cancer
09 juil. 2020 18h43 HE
|
MacroGenics, Inc.
Rockville, MD, July 09, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Presentation of Preclinical Data at the 2020 AACR Annual Meeting
22 juin 2020 09h00 HE
|
MacroGenics, Inc.
Rockville, MD, June 22, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Margetuximab Granted Orphan Drug Designation in the U.S. for Gastric Cancer
05 juin 2020 07h30 HE
|
MacroGenics, Inc.
Rockville, MD, June 05, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Publication in Science Translational Medicine Supporting Flotetuzumab Pivotal Study in Patients with Refractory Acute Myeloid Leukemia
03 juin 2020 16h05 HE
|
MacroGenics, Inc.
Rockville, MD, June 03, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Provides Update on FDA Review of Margetuximab for HER2-Positive Metastatic Breast Cancer
28 mai 2020 07h30 HE
|
MacroGenics, Inc.
- Advisory committee meeting not required; PDUFA goal date unchanged Rockville, MD, May 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical...
MacroGenics Announces Registration Study of Flotetuzumab in Patients with Refractory Acute Myeloid Leukemia
27 mai 2020 07h30 HE
|
MacroGenics, Inc.
Rockville, MD, May 27, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...